中文介紹：
Azido-PEG4-NHS ester是一種非常受歡迎的PEG試劑，它含有疊氮基團和NHS酯。親水性PEG間隔物增加了在水性介質中的溶解度。疊氮基團可以通過點擊化學與炔、BCN、DBCO反應，產生穩(wěn)定的三唑鍵。NHS酯可用于標記蛋白質的伯胺（-NH2）、胺修飾的寡核苷酸和其他含胺分子。
英文介紹：
Azido-PEG4-NHS ester is a very popular PEG reagent which containan azide group and an NHS ester. The hydrophilic PEG spacer increases solubility in aqueous media. The azide group can react with alkyne, BCN, DBCO via Click Chemistry to yield a stable triazole linkage. The NHS ester can be used to label the primary amines (-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules. Reagent grade, for research purpose. Please contact us for GMP-grade inquiries.
產品詳情：
Azido-PEG4-NHS Ester 疊氮-四聚乙二醇-NHS脂 CAS944251-24-5
產品英文名稱：Azido-PEG4-NHS Ester
產品中文名稱：疊氮-四聚乙二醇-乙烯酸琥珀酰亞胺
分子量：388.37
分子式：C15H24N4O8
CAS:944251-24-5
溶解度：DMSO、DMF、DCM、THF、氯仿
純度>95%（液相色譜法）
外觀：無色至微黃色油
儲存條件：-20°C.干燥劑
裝運條件環(huán)境溫度
描述：Azido-PEG4-NHS酯是一種標記試劑，可用于通過穩(wěn)定的酰胺鍵修飾帶有Azido基的伯胺基（例如，賴氨酸殘基的側鏈或氨基硅烷涂層表面）。疊氮化物（N3）基團通過CuAAC與末端炔烴反應，通過無銅點擊反應與應變環(huán)辛基（例如DBCO或BCN化合物）反應，或通過一種稱為Staudinger化學的機制與膦標記分子反應，從而實現(xiàn)生物樣品中衍生分子的和特異的共軛。
產品被引文獻：
1.Brunel, L. G., Cai, B., Hull, S. M., Han, U., Wungcharoen, T., Fernandes-Cunha, G. M., ... & Myung, D. (2024). In Situ UNIversal Orthogonal Network (UNION) Bioink Deposition for Direct Delivery of Corneal Stromal Stem Cells to Corneal Wounds. bioRxiv, 2024-09.
doi.org/10.1101/2024.09.19.613997
2.Brunel, L. G., Long, C. M., Christakopoulos, F., Cai, B., Johansson, P. K., Singhal, D., ... & Heilshorn, S. C. (2024). Interpenetrating networks of fibrillar and amorphous collagen promote cell spreading and hydrogel stability. bioRxiv, 2024-09.
doi.org/10.1101/2024.09.11.612534
3.Hull SM, Lindsay CD, et al 3D Bioprinting using UNIversal Orthogonal Network (UNION) Bioinks. Advanced Functional Materials. 2021. 31(7). 2007983
doi/am-pdf/10.1002/adfm.202007983
4.Mapes, J. H., Stover, J., Stout, H. D., Folsom, T. M., Babcock, E., Loudwig, S., ... & Swaminathan, J. (2023). Robust and scalable single-molecule protein sequencing with fluorosequencing. bioRxiv, 2023-09.
biorxiv.org/content/10.1101/2023.09.15.558007v1.full.pdf
